TY - JOUR
T1 - Clinical Evolution in Patients With New-Onset Inflammatory Back Pain
T2 - A Population-Based Cohort Study
AU - Wang, Runsheng
AU - Crowson, Cynthia S.
AU - Wright, Kerry
AU - Ward, Michael M.
N1 - Funding Information:
Supported in part by the NIH (Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases) and the Rheumatology Research Foundation (Scientist Development Award). Funding was also provided through the Rochester Epidemiology Project, which is supported by the NIH (National Institute on Aging grant R01-AG-034676 and Clinical and Translational Science Award UL1-TR-000135 from the National Center for Advancing Translational Sciences).
Publisher Copyright:
© 2018, American College of Rheumatology
PY - 2018/7
Y1 - 2018/7
N2 - Objective: Inflammatory back pain (IBP) is often an early manifestation of spondyloarthritis (SpA), but the prognosis of patients with incident IBP is unknown. This study was undertaken to investigate long-term outcomes in patients with IBP, and predictors of progression to SpA, in a population-based cohort. Methods: We conducted a retrospective, longitudinal study using the Rochester Epidemiology Project, a longstanding population-based cohort of residents of Olmsted County, MN. Patients ages 16–35 years with clinical visits for back pain from 1999 to 2003 were identified, and we screened these patients for the presence of new-onset IBP and performed medical record reviews to collect data on clinical, laboratory, and imaging features of SpA. Outcomes in these patients were followed up until July 2016. We used survival analysis for competing risks to examine progression to either SpA, a non-SpA diagnosis, or resolution of back pain. Recursive partitioning was used to identify predictors of progression to SpA. Results: Among 5,304 patients with back pain, we identified 124 patients with new-onset IBP. After a median follow-up of 13.2 years, IBP had progressed to SpA in 39 patients, 15 patients developed a non-SpA diagnosis, and 58 patients had resolution of IBP. At 10 years, the probability of having SpA was 30%, while the probability of resolution of IBP was 43%. The most important predictors for progression to SpA were uveitis, male sex, and family history of SpA. Conclusion: In a minority of patients, new-onset IBP progresses to SpA, while IBP resolves in many. That IBP often resolves may explain the difference between the prevalence of IBP (3–6%) and the prevalence of SpA (0.4–1.3%).
AB - Objective: Inflammatory back pain (IBP) is often an early manifestation of spondyloarthritis (SpA), but the prognosis of patients with incident IBP is unknown. This study was undertaken to investigate long-term outcomes in patients with IBP, and predictors of progression to SpA, in a population-based cohort. Methods: We conducted a retrospective, longitudinal study using the Rochester Epidemiology Project, a longstanding population-based cohort of residents of Olmsted County, MN. Patients ages 16–35 years with clinical visits for back pain from 1999 to 2003 were identified, and we screened these patients for the presence of new-onset IBP and performed medical record reviews to collect data on clinical, laboratory, and imaging features of SpA. Outcomes in these patients were followed up until July 2016. We used survival analysis for competing risks to examine progression to either SpA, a non-SpA diagnosis, or resolution of back pain. Recursive partitioning was used to identify predictors of progression to SpA. Results: Among 5,304 patients with back pain, we identified 124 patients with new-onset IBP. After a median follow-up of 13.2 years, IBP had progressed to SpA in 39 patients, 15 patients developed a non-SpA diagnosis, and 58 patients had resolution of IBP. At 10 years, the probability of having SpA was 30%, while the probability of resolution of IBP was 43%. The most important predictors for progression to SpA were uveitis, male sex, and family history of SpA. Conclusion: In a minority of patients, new-onset IBP progresses to SpA, while IBP resolves in many. That IBP often resolves may explain the difference between the prevalence of IBP (3–6%) and the prevalence of SpA (0.4–1.3%).
UR - http://www.scopus.com/inward/record.url?scp=85047422708&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047422708&partnerID=8YFLogxK
U2 - 10.1002/art.40460
DO - 10.1002/art.40460
M3 - Article
C2 - 29471593
AN - SCOPUS:85047422708
SN - 2326-5191
VL - 70
SP - 1049
EP - 1055
JO - Arthritis and Rheumatology
JF - Arthritis and Rheumatology
IS - 7
ER -